Efficacy and safety of lemborexant in midlife women with insomnia disorder.

LSM treatment differences (LEM-PBO) from baseline to month 6 again were all in the direction that favored LEM5 (LSM difference [95% CI], −12.43 [−31.95 to 7.09]) and LEM10 (−9.94 [−28.18 to 8.30]) versus PBO; however, these differences did not reach statistical significance (Table 2 ; Fig. 1 C).

also in 111,027 other papers